Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics

Toxicology in Vitro

Volumn 30, Issue 1, 2015, Pages 117-127

  Wilmes, Anja ^a   Bielow, Chris ^b   Ranninger, Christina ^c   Bellwon, Patricia ^d   Aschauer, Lydia ^a   Limonciel, Alice ^a   Chassaigne, Hubert ^e   Kristl, Theresa ^c   Aiche, Stephan ^b   Huber, Christian G ^d   Guillou, Claude ^e   Hewitt, Philipp ^f   Leonard, Martin O ^g   Dekant, Wolfgang ^d   Bois, Frederic ^h   Jennings, Paul ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY OF SALZBURG   (Austria)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e JOINT RESEARCH CENTRE   (Italy)

^f Merck Serono GmbH   (Germany)

^g PUBLIC HEALTH ENGLAND   (United Kingdom)

^h UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

Author keywords

Autophagy; Biokinetics; Cisplatin; Omics; Proximal tubule; Stress response pathways

Indexed keywords

ACTIN; CISPLATIN; GAMMA GLUTAMYLTRANSFERASE; HYBRID PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INITIATION FACTOR 2; MAMMALIAN TARGET OF RAPAMYCIN; MESENCEPHALIC ASTROCYTE DERIVED NEUROTROPHIC FACTOR; ORGANIC CATION TRANSPORTER 2; PROTEIN P53; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; WASP PROTEIN; TRANSCRIPTOME;

APICAL COMPARTMENT; ARTICLE; BASOLATERAL COMPARTMENT; BIOKINETICS; CELL COMPARTMENTALIZATION; CELL POLARIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ACTIVATION; DRUG TRANSPORT; HUMAN; HUMAN CELL; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; KINETICS; METABOLOMICS; MITOCHONDRION; NEPHROTOXICITY; OXIDATIVE STRESS; POLARIZATION; PROTEOMICS; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; BIOLOGICAL MODEL; CELL LINE; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; PHYSIOLOGY;

CELL LINE; CISPLATIN; GENE EXPRESSION REGULATION; HUMANS; KIDNEY TUBULES, PROXIMAL; METABOLIC NETWORKS AND PATHWAYS; METABOLOMICS; MODELS, BIOLOGICAL; PROTEOMICS; TRANSCRIPTOME;

EID: 84973558678     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2014.10.006     Document Type: Article

References (68)

1. Ahuja V., Sharma S. Drug safety testing paradigm, current progress and future challenges: an overview. J. Appl. Toxicol. 2014, 34:576-594.
2. Altun Z., Olgun Y., Ercetin P., Aktas S., Kirkim G., Serbetcioglu B., Olgun N., Guneri E.A. Protective effect of acetyl-l-carnitine against cisplatin ototoxicity: role of apoptosis-related genes and pro-inflammatory cytokines. Cell Prolif. 2014, 47:72-80.
3. Aschauer L., Gruber L.N., Pfaller W., Limonciel A., Athersuch T.J., Cavill R., Khan A., Gstraunthaler G., Grillari J., Grillari R., Hewitt P., Leonard M.O., Wilmes A., Jennings P. Delineation of the key aspects in the regulation of epithelial monolayer formation. Mol. Cell. Biol. 2013, 33:2535-2550.
4. Bois F.Y. GNU MCSim: Bayesian statistical inference for SBML-coded systems biology models. Bioinformatics 2009, 25:1453-1454.
5. Bois F.Y., Jamei M., Clewell H.J. PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. Toxicology 2010, 278:256-267.
6. Braissant O., Foufelle F., Scotto C., Dauca M., Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996, 137:354-366.
7. Bu W., Lim K.B., Yu Y.H., Chou A.M., Sudhaharan T., Ahmed S. Cdc42 interaction with N-WASP and Toca-1 regulates membrane tubulation, vesicle formation and vesicle motility: implications for endocytosis. PLoS One 2010, 5:e12153.
8. Ciarimboli G., Ludwig T., Lang D., Pavenstadt H., Koepsell H., Piechota H.J., Haier J., Jaehde U., Zisowsky J., Schlatter E. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol. 2005, 167:1477-1484.
9. Conner S.D., Schmid S.L. Regulated portals of entry into the cell. Nature 2003, 422:37-44.
10. Cox J., Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 2008, 26:1367-1372.
11. Crighton D., Wilkinson S., O'Prey J., Syed N., Smith P., Harrison P.R., Gasco M., Garrone O., Crook T., Ryan K.M. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006, 126:121-134.
12. Diradourian C., Girard J., Pegorier J.P. Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie 2005, 87:33-38.
13. Dobyan D.C., Levi J., Jacobs C., Kosek J., Weiner M.W. Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J. Pharmacol. Exp. Ther. 1980, 213:551-556.
14. dos Santos N.A., Carvalho Rodrigues M.A., Martins N.M., dos Santos A.C. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch. Toxicol. 2012, 86:1233-1250.
15. Dupont J., Reverchon M., Cloix L., Froment P., Rame C. Involvement of adipokines, AMPK, PI3K and the PPAR signaling pathways in ovarian follicle development and cancer. Int. J. Dev. Biol. 2012, 56:959-967.
16. El-Awady el S.E., Moustafa Y.M., Abo-Elmatty D.M., Radwan A. Cisplatin-induced cardiotoxicity: mechanisms and cardioprotective strategies. Eur. J. Pharmacol. 2011, 650:335-341.
17. Feng Z. P53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. Cold Spring Harb. Perspect. Biol. 2010, 2:a001057.
18. Feng Z., Zhang H., Levine A.J., Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc. Natl. Acad. Sci. USA 2005, 102:8204-8209.
19. Fingar D.C., Richardson C.J., Tee A.R., Cheatham L., Tsou C., Blenis J. MTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol. 2004, 24:200-216.
20. Fukata M., Nakagawa M., Kaibuchi K. Roles of Rho-family GTPases in cell polarisation and directional migration. Curr. Opin. Cell Biol. 2003, 15:590-597.
21. Gao L., Joberty G., Macara I.G. Assembly of epithelial tight junctions is negatively regulated by Par6. Curr. Biol. 2002, 12:221-225.
22. Hardie D.G., Pan D.A. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem. Soc. Trans. 2002, 30:1064-1070.
23. Harhaji-Trajkovic L., Vilimanovich U., Kravic-Stevovic T., Bumbasirevic V., Trajkovic V. AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumour cells. J. Cell. Mol. Med. 2009, 13:3644-3654.
24. Harris K.P., Tepass U. Cdc42 and vesicle trafficking in polarized cells. Traffic 2010, 11:1272-1279.
25. Hurd T.W., Fan S., Liu C.J., Kweon H.K., Hakansson K., Margolis B. Phosphorylation-dependent binding of 14-3-3 to the polarity protein Par3 regulates cell polarity in mammalian epithelia. Curr. Biol. 2003, 13:2082-2090.
26. Ide T., Chu K., Aaronson S.A., Lee S.W. GAMT joins the p53 network: branching into metabolism. Cell Cycle 2010, 9:1706-1710.
27. Ikeda Y., Taniguchi N. Gene expression of gamma-glutamyltranspeptidase. Meth. Enzymol. 2005, 401:408-425.
28. Inoki K., Zhu T., Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590.
29. Ishida S., Lee J., Thiele D.J., Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc. Natl. Acad. Sci. USA 2002, 99:14298-14302.
30. Jennings P. Stress response pathways, toxicity pathways and adverse outcome pathways. Arch. Toxicol. 2013, 87:13-14.
31. Jennings P., Limonciel A., Felice L., Leonard M.O. An overview of transcriptional regulation in response to toxicological insult. Arch. Toxicol. 2013, 87:49-72.
32. Jiang M., Wei Q., Dong G., Komatsu M., Su Y., Dong Z. Autophagy in proximal tubules protects against acute kidney injury. Kidney Int. 2012, 82:1271-1283.
33. Joberty G., Petersen C., Gao L., Macara I.G. The cell-polarity protein Par6 links Par3 and atypical protein kinase C to Cdc42. Nat. Cell Biol. 2000, 2:531-539.
34. Kaushal G.P., Kaushal V., Herzog C., Yang C. Autophagy delays apoptosis in renal tubular epithelial cells in cisplatin cytotoxicity. Autophagy 2008, 4:710-712.
35. Lancaster C.S., Hu C., Franke R.M., Filipski K.K., Orwick S.J., Chen Z., Zuo Z., Loos W.J., Sparreboom A. Cisplatin-induced downregulation of OCTN2 affects carnitine wasting. Clin. Cancer Res. 2010, 16:4789-4799.
36. Li J., Xu Z., Jiang L., Mao J., Zeng Z., Fang L., He W., Yuan W., Yang J., Dai C. Rictor/mTORC2 protects against cisplatin-induced tubular cell death and acute kidney injury. Kidney Int. 2014, 86(1):86-102. 10.1038/ki.2013.559.
37. Limonciel A., Aschauer L., Wilmes A., Prajczer S., Leonard M.O., Pfaller W., Jennings P. Lactate is an ideal non-invasive marker for evaluating temporal alterations in cell stress and toxicity in repeat dose testing regimes. Toxicol. In Vitro 2011, 25:1855-1862.
38. Limonciel A., Wilmes A., Aschauer L., Radford R., Bloch K.M., McMorrow T., Pfaller W., van Delft J.H., Slattery C., Ryan M.P., Lock E.A., Jennings P. Oxidative stress induced by potassium bromate exposure results in altered tight junction protein expression in renal proximal tubule cells. Arch. Toxicol. 2012, 86:1741-1751.
39. Ludwig T., Riethmuller C., Gekle M., Schwerdt G., Oberleithner H. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int. 2004, 66:196-202.
40. Ma L., Rohatgi R., Kirschner M.W. The Arp2/3 complex mediates actin polymerization induced by the small GTP-binding protein Cdc42. Proc. Natl. Acad. Sci. USA 1998, 95:15362-15367.
41. Miller R.P., Tadagavadi R.K., Ramesh G., Reeves W.B. Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2010, 2:2490-2518.
42. Nakamura T., Yonezawa A., Hashimoto S., Katsura T., Inui K. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem. Pharmacol. 2010, 80:1762-1767.
43. Ognjanovic B.I., Djordjevic N.Z., Matic M.M., Obradovic J.M., Mladenovic J.M., Stajn A.S., Saicic Z.S. Lipid peroxidative damage on cisplatin exposure and alterations in antioxidant defense system in rat kidneys: a possible protective effect of selenium. Int. J. Mol. Sci. 2012, 13:1790-1803.
44. Okuda M., Saito H., Urakami Y., Takano M., Inui K. CDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochem. Biophys. Res. Commun. 1996, 224:500-507.
45. Pabla N., Murphy R.F., Liu K., Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am. J. Physiol. Renal Physiol. 2009, 296:F505-F511.
46. Peres L.A., da Cunha A.D. Acute nephrotoxicity of cisplatin: molecular mechanisms. J. Bras. Nefrol. 2013, 35:332-340.
47. Pieczynski J., Margolis B. Protein complexes that control renal epithelial polarity. Am. J. Physiol. Renal Physiol. 2011, 300:F589-601.
48. Qian W., Nishikawa M., Haque A.M., Hirose M., Mashimo M., Sato E., Inoue M. Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death. Am. J. Physiol. Cell Physiol. 2005, 289:C1466-1475.
49. Rodrigues M.A., Rodrigues J.L., Martins N.M., Barbosa F., Curti C., Santos N.A., Santos A.C. Carvedilol protects against the renal mitochondrial toxicity induced by cisplatin in rats. Mitochondrion 2010, 10:46-53.
50. Rovetta F., Stacchiotti A., Consiglio A., Cadei M., Grigolato P.G., Lavazza A., Rezzani R., Aleo M.F. ER signaling regulation drives the switch between autophagy and apoptosis in NRK-52E cells exposed to cisplatin. Exp. Cell Res. 2012, 318:238-250.
51. Sancho-Martinez S.M., Prieto-Garcia L., Prieto M., Lopez-Novoa J.M., Lopez-Hernandez F.J. Subcellular targets of cisplatin cytotoxicity: an integrated view. Pharmacol. Ther. 2012, 136:35-55.
52. Santos N.A., Catao C.S., Martins N.M., Curti C., Bianchi M.L., Santos A.C. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch. Toxicol. 2007, 81:495-504.
53. Sieber M., Hoffmann D., Adler M., Vaidya V.S., Clement M., Bonventre J.V., Zidek N., Rached E., Amberg A., Callanan J.J., Dekant W., Mally A. Comparative analysis of novel noninvasive renal biomarkers and metabonomic changes in a rat model of gentamicin nephrotoxicity. Toxicol. Sci. 2009, 109:336-349.
54. Sumner L.W., Amberg A., Barrett D., Beale M.H., Beger R., Daykin C.A., Fan T.W., Fiehn O., Goodacre R., Griffin J.L., Hankemeier T., Hardy N., Harnly J., Higashi R., Kopka J., Lane A.N., Lindon J.C., Marriott P., Nicholls A.W., Reily M.D., Thaden J.J., Viant M.R. Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics 2007, 3:211-221.
55. Townsend D.M., Deng M., Zhang L., Lapus M.G., Hanigan M.H. Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J. Am. Soc. Nephrol. 2003, 14:1-10.
56. Tufekci O., Gunes D., Ozogul C., Kolatan E., Altun Z., Yilmaz O., Aktas S., Erbayraktar Z., Kirkim G., Mutafoglu K., Soylu A., Serbetcioglu B., Guneri E.A., Olgun N. Evaluation of the effect of acetyl l-carnitine on experimental cisplatin nephrotoxicity. Chemotherapy 2009, 55:451-459.
57. Wang D., Lippard S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 2005, 4:307-320.
58. Welch M.D. The world according to Arp: regulation of actin nucleation by the Arp2/3 complex. Trends Cell Biol. 1999, 9:423-427.
59. Wen X., Buckley B., McCandlish E., Goedken M.J., Syed S., Pelis R., Manautou J.E., Aleksunes L.M. Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice. Am. J. Pathol. 2014, 184:1299-1308.
60. Wieser M., Stadler G., Jennings P., Streubel B., Pfaller W., Ambros P., Riedl C., Katinger H., Grillari J., Grillari-Voglauer R. HTERT alone immortalizes epithelial cells of renal proximal tubules without changing their functional characteristics. Am. J. Physiol. Renal Physiol. 2008, 295:F1365-1375.
61. Wilmes A., Crean D., Aydin S., Pfaller W., Jennings P., Leonard M.O. Identification and dissection of the Nrf2 mediated oxidative stress pathway in human renal proximal tubule toxicity. Toxicol. In Vitro 2011, 25:613-622.
62. Wilmes A., Limonciel A., Aschauer L., Moenks K., Bielow C., Leonard M.O., Hamon J., Carpi D., Ruzek S., Handler A., Schmal O., Herrgen K., Bellwon P., Burek C., Truisi G.L., Hewitt P., Di Consiglio E., Testai E., Blaauboer B.J., Guillou C., Huber C.G., Lukas A., Pfaller W., Mueller S.O., Bois F.Y., Dekant W., Jennings P. Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. J. Proteomics 2013, 79:180-194.
63. Wilmes A., Aschauer L., Limonciel A., Pfaller W., Jennings P. Evidence for a role of claudin 2 as a proximal tubular stress responsive paracellular water channel. Toxicol. Appl. Pharmacol. 2014, 279(2):163-172. 10.1016/j.taap.2014.05.013.
64. Yang Z., Schumaker L.M., Egorin M.J., Zuhowski E.G., Guo Z., Cullen K.J. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin. Cancer Res. 2006, 12:5817-5825.
65. Yang C., Kaushal V., Shah S.V., Kaushal G.P. Autophagy is associated with apoptosis in cisplatin injury to renal tubular epithelial cells. Am. J. Physiol. Renal Physiol. 2008, 294:F777-787.
66. Zhang B., Ramesh G., Norbury C.C., Reeves W.B. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int. 2007, 72:37-44.
67. Zhang X.D., Qin Z.H., Wang J. The role of p53 in cell metabolism. Acta Pharmacol. Sin. 2010, 31:1208-1212.
68. Zhou H., Huang S. The complexes of mammalian target of rapamycin. Curr. Protein Pept. Sci. 2010, 11:409-424.